Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Apr;114(4):501-515.
doi: 10.1016/j.ymgme.2014.12.434. Epub 2014 Dec 29.

A clinical approach to the diagnosis of patients with leukodystrophies and genetic leukoencephelopathies

Sumit Parikh #  1 , Geneviève Bernard #  2 , Richard J Leventer  3 , Marjo S van der Knaap  4 , Johan van Hove  5 , Amy Pizzino  6 , Nathan H McNeill  7 , Guy Helman  6 , Cas Simons  8 , Johanna L Schmidt  6 , William B Rizzo  9 , Marc C Patterson #  9 , Ryan J Taft #  8   10   11 , Adeline Vanderver #  6   12   10 ; GLIA Consortium
Affiliations
Review

A clinical approach to the diagnosis of patients with leukodystrophies and genetic leukoencephelopathies

Sumit Parikh et al. Mol Genet Metab. 2015 Apr.

Abstract

Leukodystrophies (LD) and genetic leukoencephalopathies (gLE) are disorders that result in white matter abnormalities in the central nervous system (CNS). Magnetic resonance (MR) imaging (MRI) has dramatically improved and systematized the diagnosis of LDs and gLEs, and in combination with specific clinical features, such as Addison's disease in Adrenoleukodystrophy or hypodontia in Pol-III related or 4H leukodystrophy, can often resolve a case with a minimum of testing. The diagnostic odyssey for the majority LD and gLE patients, however, remains extensive--many patients will wait nearly a decade for a definitive diagnosis and at least half will remain unresolved. The combination of MRI, careful clinical evaluation and next generation genetic sequencing holds promise for both expediting the diagnostic process and dramatically reducing the number of unresolved cases. Here we present a workflow detailing the Global Leukodystrophy Initiative (GLIA) consensus recommendations for an approach to clinical diagnosis, including salient clinical features suggesting a specific diagnosis, neuroimaging features and molecular genetic testing. We also discuss recommendations on the use of broad-spectrum next-generation sequencing in instances of ambiguous MRI or clinical findings. We conclude with a proposal for systematic trials of genome-wide agnostic testing as a first line diagnostic in LDs and gLEs given the increasing number of genes associated with these disorders.

Keywords: Glia; Leukodystrophy; Myelin.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Recommended molecular diagnostic workflow. Note emphasis on identification of treatable disorders to enable rapid changes in care as appropriate. For a complete description of this figure please see the main text. Abbreviations: P = pathogenic; LP = likely pathogenic.
Fig. 2
Fig. 2
MRI pattern recognition in the LD and gLE (reprinted with permission from Genereviews). Three major MRI characteristics help to discriminate between the different types of LD and gLE. The first discriminator is the presence or absence of hypomyelination (Fig. 2a). Within this subset, the presence of improvement of myelination or atrophy directs the clinician towards a series of gLEs. Within the true hypomyelinating LDs, the presence of basal ganglia and cerebellar involvement further helps refine the diagnosis. If the pattern is not one of hypomyelination, then the second discriminator is whether the white matter abnormalities are confluent or isolated and multifocal (Fig. 2b). If the white matter abnormalities are confluent, then the third discriminator is the predominant localization of the abnormalities (Fig. 2b).
Fig. 2
Fig. 2
MRI pattern recognition in the LD and gLE (reprinted with permission from Genereviews). Three major MRI characteristics help to discriminate between the different types of LD and gLE. The first discriminator is the presence or absence of hypomyelination (Fig. 2a). Within this subset, the presence of improvement of myelination or atrophy directs the clinician towards a series of gLEs. Within the true hypomyelinating LDs, the presence of basal ganglia and cerebellar involvement further helps refine the diagnosis. If the pattern is not one of hypomyelination, then the second discriminator is whether the white matter abnormalities are confluent or isolated and multifocal (Fig. 2b). If the white matter abnormalities are confluent, then the third discriminator is the predominant localization of the abnormalities (Fig. 2b).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Adulthood leukodystrophies.
    Köhler W, Curiel J, Vanderver A. Köhler W, et al. Nat Rev Neurol. 2018 Feb;14(2):94-105. doi: 10.1038/nrneurol.2017.175. Epub 2018 Jan 5. Nat Rev Neurol. 2018. PMID: 29302065 Free PMC article. Review.
  • Inherited paediatric neurometabolic disorders, can brain magnetic resonance imaging predict?
    Al Orf A, Waheed KB, Ali EM, Muhammad AK, Al Zahrani FM, Seth SA, Al Jubair NN, Harisi HS, Arulanantham ZJ. Al Orf A, et al. Neurosciences (Riyadh). 2020 Oct;25(5):392-398. doi: 10.17712/nsj.2020.5.20200072. Neurosciences (Riyadh). 2020. PMID: 33459289 Free PMC article.
  • POLR3-Related Leukodystrophy: Exploring Potential Therapeutic Approaches.
    Perrier S, Michell-Robinson MA, Bernard G. Perrier S, et al. Front Cell Neurosci. 2021 Jan 28;14:631802. doi: 10.3389/fncel.2020.631802. eCollection 2020. Front Cell Neurosci. 2021. PMID: 33633543 Free PMC article.
  • Disease specific therapies in leukodystrophies and leukoencephalopathies.
    Helman G, Van Haren K, Bonkowsky JL, Bernard G, Pizzino A, Braverman N, Suhr D, Patterson MC, Ali Fatemi S, Leonard J, van der Knaap MS, Back SA, Damiani S, Goldman SA, Takanohashi A, Petryniak M, Rowitch D, Messing A, Wrabetz L, Schiffmann R, Eichler F, Escolar ML, Vanderver A; GLIA Consortium. Helman G, et al. Mol Genet Metab. 2015 Apr;114(4):527-36. doi: 10.1016/j.ymgme.2015.01.014. Epub 2015 Feb 7. Mol Genet Metab. 2015. PMID: 25684057 Free PMC article.
  • Practical Approaches and Knowledge Gaps in the Care for Children With Leukodystrophies.
    Keller SR, Mallack EJ, Rubin JP, Accardo JA, Brault JA, Corre CS, Elizondo C, Garafola J, Jackson-Garcia AC, Rhee J, Seeger E, Shullanberger KC, Tourjee A, Trovato MK, Waldman AT, Wallace JL, Wallace MR, Werner K, White A, Ess KC, Becker C, Eichler FS. Keller SR, et al. J Child Neurol. 2021 Jan;36(1):65-78. doi: 10.1177/0883073820946154. Epub 2020 Sep 2. J Child Neurol. 2021. PMID: 32875938 Free PMC article. Review.
See all "Cited by" articles

References

    1. Vanderver A, Tonduti D, Schiffmann R, Schmidt J, Van der Knaap MS. Leukodys-trophy overview. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, editors. GeneReviews(R) University of Washington, Seattle University of Washington; Seattle: 2014. All rights reserved., Seattle (WA) - PubMed
    1. Vanderver A, Prust M, Tonduti D, Mochel F, Hussey H, Helman G, Garbern J, Eichler F, Labauge P, Aubourg P, Rodriguez D, Patterson M, Van Hove J, Schmidt J, Wolf N, Boespflug-Tanguy O, Schiffmann R, van der Knaap M. Case definition and classification of leukodystrophies and leukoencephalopathies. Mol. Genet. Metab. 2014 in press. - PMC - PubMed
    1. Heim P, Claussen M, Hoffmann B, Conzelmann E, Gärtner J, Harzer K, Hunneman DH, Köhler W, Kurlemann G, Kohlschütter A. Leukodystrophy incidence in Germany. Am. J. Med. Genet. 1997;71:475–478. - PubMed
    1. Bonkowsky JL, Nelson C, Kingston JL, Filloux FM, Mundorff MB, Srivastava R. The burden of inherited leukodystrophies in children. Neurology. 2010;75:718–725. - PMC - PubMed
    1. Bernard G, Vanderver A. Pol III-related leukodystrophies. 2012

Publication types

MeSH terms